CeraVe and La Roche-Posay acne treatments allegedly break down into benzene, a known carcinogen

Case

Defendant

L'Oréal USA, Inc. (CeraVe, La Roche-Posay)

Plaintiff

Consolidated consumer classes (7 actions, lead Noakes v. L'Oréal)

Court

U.S. District Court, S.D.N.Y. (In re L'Oréal Benzoyl Peroxide Products Litigation, No. 1:24-cv-02735)

Filed

Mar 8, 2024

Status

Ongoing

Outcome

pending — motion to dismiss fully briefed Feb. 2026, awaiting decision; no merits rulings, no settlement

Industry

Personal care

The Allegation

Seven consumer class actions consolidated before Judge Analisa Torres (In re L'Oréal Benzoyl Peroxide Products Litigation, S.D.N.Y.) allege that benzoyl peroxide in CeraVe Acne Foaming Cream Cleanser/Wash and La Roche-Posay Effaclar Duo degrades into benzene: Valisure's March 2024 testing found ~5–12 ppm in CeraVe products and over 100 ppm in Effaclar Duo under hot-storage incubation, versus FDA's 2 ppm limit. FDA's own March 2025 testing found >90% of acne products at very low levels but still prompted a retail recall of one Effaclar Duo lot (2.2M units); L'Oréal pulled the benzoyl peroxide Effaclar Duo from the U.S. market and reformulated. The economic-loss suits are pending — L'Oréal's motion to dismiss was fully briefed in February 2026 and awaits decision.

Scout Impact

Benzoyl peroxide's instability is chemistry users can act on today — heat exposure accelerates benzene formation — and it's exactly why Scout already caps scores on benzoyl peroxide products. A live consolidated case against the biggest skincare brands makes that cap's rationale visible.